Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: tRF3008A suppresses the progression and metastasis of colorectal cancer by destabilizing FOXK1 in an AGO-dependent manner

Fig. 6

tRF3008A as a Novel Predictive Biomarker for colorectal cancer. A The expression of tRF3008A and FOXK1 was validated in a subset of 45 pairs of CRC and adjacent non-tumorous tissues. DFS analysis was performed by the Kaplan–Meier test and the log-rank method in the training cohort. B The expression of tRF3008A in plasma before and after surgery in 22 CRC patients was analyzed by qRT-PCR. C. RT-PCR was conducted to validate the expression of tRF3008A between CRC patients in clinical stages I-III (n = 22) and CRC patients in clinical stage IV (n = 12). D qPCR was performed to evaluate the expression correlation between tRF3008A and FOXK1 in CRC tissues and blood samples in the validation cohort (n = 22); Spearman’s rank correlation test was used. ***: P < 0.001. E Proposed working model. Schematic summarizing our proposed model for tRF3008A-mediated inhibition of the Wnt pathway in colorectal cancer cells. tRF-3008A binds to AGO proteins and induces subsequent destabilization of FOXK1 mRNA, which blocks the activation of Wnt signaling and EMT in colorectal cancer cells

Back to article page